alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 801–825 of 2,047 studies published 2026 (page 33 of 82) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Loss of Proteostasis and Early-Onset Neurodegeneration in Down Syndrome: From Mechanisms to Interventions

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Antioxidants (Basel, Switzerland) 2026-04-21

Down syndrome (DS), caused by trisomy 21, is the most prevalent genetic condition associated with accelerated aging and near-universal development of early-onset Alzheimer's disease (AD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Loss of Proteostasis and Abnormal Aging in Down Syndrome: From Mechanisms to Interventions

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Antioxidants (Basel, Switzerland) 2026-03-17

Down syndrome (DS), caused by trisomy 21, is the most prevalent genetic condition associated with accelerated aging and near-universal development of early-onset Alzheimer’s disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Epilepsy and Alzheimer Disease: Epidemiologic, Clinical, Molecular, and Neuropathologic Convergences and Divergences

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Neurology. Clinical practice 2026-02-26

Alzheimer disease (AD) and epilepsy are major causes of neurologic disability and are reciprocally related: epileptiform discharges, subclinical seizures, and epilepsy are more prevalent in patients with AD compared with controls; progressive cognitive impairment commonly afflicts epilepsy patients; and late-onset epilepsy patients have higher rates of new-onset dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of managed care & specialty pharmacy 2026-04-01

All recently approved monoclonal antibodies (eg, aducanumab, lecanemab, and donanemab) for Alzheimer disease (AD) were shown to increase the risks of amyloid-related imaging abnormalities (ARIA) in randomized clinical trials, which can include brain swelling or hemorrhage. 4 key findings →

Participants: 240 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of residential neighborhood disadvantage with amyloid PET positivity among cognitively impaired individuals

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia Behavior & Socioeconomics of Aging 2026-01-29

Residence in the most disadvantaged neighborhoods may be associated with lower amyloid pathology in cognitively impaired individuals. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Agricultural pesticide use and Alzheimer’s disease dementia prevalence across US counties in a mixed supervised–unsupervised analysis

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Scientific Reports 2026-06-11

Agricultural pesticide use represents one of the most geographically patterned environmental systems, yet most prior research has focused largely on individual compounds rather than correlated exposure regimes. 3 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting Alzheimer progression using EEG-based digital twins

✓ Peer-reviewed alzhub usefulness score 39 out of 100. npj Digital Medicine 2026-08-03

Early and accurate prognosis of Alzheimer’s disease (AD) remains limited by current biomarkers, which are often invasive, require expensive equipment, or fail to predict individual trajectories of cognitive decline. 2 key findings →

Participants: 459 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Associations of gut bacterial classes Clostridia and Deltaproteobacteria with type 2 diabetes and Alzheimer’s disease: A two-sample Mendelian randomization study

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Medicine 2026-05-15

Using a 2-sample Mendelian randomization (MR) approach, we evaluated MR evidence for genetically proxied effects of 10 pre-specified gut bacterial classes on type 2 diabetes mellitus (T2DM) and Alzheimer disease (AD), and assessed MR evidence for a direct genetically proxied effect of T2DM on AD. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Neurology 2026-05-01

Although β-site APP-cleaving enzyme 1 (BACE1) and secretase inhibitors did not achieve success in clinical trials because of mechanism-based toxicity and cognitive impairment, new monoclonal antibodies such as lecanemab and donanemab have shown high amyloid plaque clearance and reduced cognitive deterioration. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Measurement differences in the Harmonized Cognitive Assessment Protocol across ethnicity and language in the United States

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Neuropsychology 2026-02-09

We observed measurement differences in the HCAP across H/L and NHW older adults for the memory, language, executive functioning, and orientation, but not visuospatial, domains. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comparing phenotypic features between Parkinson’s disease dementia and dementia with Lewy bodies

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Neurology 2026-02-01

Patients with PDD showed a more severe phenotype than those with DLB, with higher scores in motor severity, hallucinations, delusions, somnolence, and urinary dysfunction (all p≤0.01). 5 key findings →

Participants: 31 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

How does Australian primary care face dementia? Identifying current practice and barriers in dementia diagnosis and management in Australian primary care – a qualitative interview study

✓ Peer-reviewed alzhub usefulness score 39 out of 100. BMC Family Practice 2026-03-21

Four themes described current primary care practitioner practices in dementia diagnosis and management (1) Family concern triggers dementia investigation (2) GPs delay conversations about dementia (3) Completing routine cognitive assessments in the 75+ health assessment, and (4) Variability in post-diagnostic care. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

AI-driven magnetoencephalography biomarkers in dementia risk prediction: current evidence, challenges and future perspectives

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Frontiers in Dementia 2026-04-07

Fourteen studies met eligibility criteria, covering populations from healthy controls to individuals with subjective cognitive decline, MCI, AD, and other dementias. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Converting short cognitive screen scores: Comparing the Quick mild cognitive impairment screen, Montreal cognitive assessment, and Mini-mental state examination

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Alzheimer s Disease Reports 2026-04-01

This study provides validated conversion tables between the Q mci screen and two widely-used cognitive instruments, to support the use of the Q mci screen in research (facilitating cross-instrument comparability and harmonization across studies), and clinical settings (determining eligibility for disease-modifying therapies). 2 key findings →

Participants: 101 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal Structural MRI-Based Deep Learning And Radiomics Features For Predicting Alzheimer\\\\\\\'s Disease Progression

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-01-01

Alzheimer\\\'s disease (AD), the leading cause of dementia worldwide, affects more than 55 million individuals and gen-erates annual healthcare costs exceeding two trillion USD [14]. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Human-Centered Ambient and Wearable Sensing for Automated Monitoring in Dementia Care: A Scoping Review

✓ Peer-reviewed alzhub usefulness score 39 out of 100. IEEE Internet of Things Journal 2026-01-22

We conducted a scoping review to map the rapidly evolving landscape of wearable and ambient sensing technologies for monitoring people with dementia across home and institutional settings. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dementia Burden and Modifiable Risk Factors in Type 2 Diabetes: Population Based, Prospective Cohort Study

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Diabetes Obesity and Metabolism 2026-03-26

T2D was associated with a higher risk and earlier onset of dementia, especially in cases with T2D diagnosed at ages 30-54 years. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Estimating cognitive function score from mild cognitive impairment to moderate dementia using a hybrid model combining plasma biomarkers with electroencephalogram signal

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Alzheimer s Disease 2026-03-13

Integrating EEG features with plasma biomarkers improves prediction of cognitive function from mild cognitive impairment to moderate dementia, pending external validation. 1 key finding →

Participants: 75 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed